Hear Repligen's CEO give company overview at June 3 webcast
Repligen (NASDAQ: RGEN), a life sciences company, announced that its President and CEO, Olivier Loeillot, will present a company overview at the William Blair 46th Annual Growth Stock Conference on June 3 at 10:40 a.m. CT. The presentation will be available via live webcast and replay on the company's Investor Relations website. This event follows a series of recent updates including earnings, sustainability reports, and operational expansions.
InvestingPro’s Fair Value model predicted Repligen’s 45% decline By Investing.com
InvestingPro's Fair Value model accurately predicted a 45% decline in Repligen Corporation's stock price between February 2024 and May 2026, flagging it as significantly overvalued despite seemingly sound fundamentals. The model's success highlights its ability to identify mispriced stocks by combining various valuation methodologies. This case study demonstrates the importance of systematic valuation analysis in helping investors avoid substantial losses.
Repligen Corp stock (US7607591002): ESG progress and growth focus draw fresh attention
Repligen Corp has released its latest sustainability update, emphasizing ambitious environmental targets such as utilizing 100% renewable electricity for manufacturing and reducing water usage. The company, a specialist in bioprocessing technologies, is also continuing to invest in high-growth bioprocessing technologies. Investors are closely monitoring how the firm's ESG progress and the ongoing demand from biotech customers will influence the stock's long-term trajectory.
Repligen Corp stock (US7607591002): ESG progress and growth focus draw fresh attention
Repligen Corp, a bioprocessing technology specialist, has released a sustainability update highlighting its ESG progress, including increased use of renewable electricity and resource efficiency. The company focuses on providing critical technologies for biologic drug production, such as filtration and chromatography solutions, serving pharmaceutical and biotech firms. Investors are observing how Repligen's ESG initiatives and demand from biotech customers will influence its long-term stock performance within the competitive bioprocessing tools industry.
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
Repligen Corporation has published its 2025 Corporate Sustainability Report, "Driving Sustainable Growth Together," detailing progress across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Pathways to Success. The report highlights achievements such as 100% renewable electricity in U.S. and European manufacturing, a double materiality assessment aligned with ESRS, and a 14% decrease in global water withdrawals. Repligen emphasizes integrating sustainability into its growth strategy to deliver lasting value for stakeholders.
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
Repligen Corporation has released its 2025 Corporate Sustainability Report, "Driving Sustainable Growth Together," detailing progress across six key impact areas including Products & Packaging, Operations, and Talent. The report includes disclosures aligned with UN SDGs, GRI Standards, SASB Standards, and TCFD, highlighting significant achievements such as maintaining 100% renewable electricity in U.S. and European manufacturing and decreasing global water withdrawals by 14%. The company's leadership emphasizes sustainability as integral to its growth and innovation.
Repligen keeps factories on 100% renewable power, cuts water use 14%
Repligen (NASDAQ: RGEN) has published its 2025 Corporate Sustainability Report, "Driving Sustainable Growth Together," highlighting significant progress in its sustainability strategy. Key achievements include maintaining 100% renewable electricity for all U.S. and European manufacturing operations and a 14% year-over-year reduction in global water withdrawals. The report also details expanded Board oversight for sustainability, new human rights and ESG policies, and the completion of its first enterprise-level Double Materiality Assessment aligned with ESRS.
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
Repligen Corporation has announced the digital publication of its 2025 Corporate Sustainability Report, themed "Driving Sustainable Growth Together." The report details the company's progress in six key impact areas and aligns with global reporting frameworks like GRI, SASB, and TCFD, now part of the IFRS Sustainability Alliance. Highlights include maintaining 100% renewable electricity in U.S. and European manufacturing, completing a Double Materiality Assessment, and decreasing global water withdrawals by 14%.
Repligen Corp (RGEN) Stock Up 4.2% and Still Undervalued -- GF S
Repligen Corp (RGEN) stock increased by 4.2% to $108.52, and according to GuruFocus's GF Value™, it remains significantly undervalued with a potential upside. The company has a strong GF Score™ of 81/100, driven by robust growth prospects, but its P/E ratio is higher than its historical median, and insiders have recently sold shares. This indicates a potential buying opportunity for value investors but also suggests caution due to valuation metrics and insider selling.
Repligen shares jump 4.1% as investors buy the dip after a sharp selloff; prior guidance update and short-covering may be factors
Repligen (RGEN) shares rose 4.1% due to investors buying the dip after a recent sharp decline, likely driven by the company's updated full-year outlook from early May and potential short-covering. Insider transactions show more sales than purchases, while institutional investors show mixed activity with major additions and removals. Analysts have issued predominantly "Buy" or "Overweight" ratings, with a median price target of $160.0.
Repligen Jumps 5.4% Amid Sector-Wide Rally
Repligen Corporation (RGEN) stock surged 5.4% to $109.80 on Tuesday, driven by a broad sector-wide rally that also boosted several of its medical instrument supplier peers. The coordinated gains suggest a rotation of investor interest back into the healthcare sector, with heightened trading volume for Repligen reflecting increased activity. No specific company news was identified as the catalyst, indicating the move is likely attributable to broader macro factors or shifting sentiment within the industry.
Repligen (RGEN) director Rohin Mhatre receives RSU and option grants
Repligen Corp. director Rohin Mhatre received 995 restricted stock units and stock options for 2,239 shares of common stock as part of routine equity compensation. After the grant, Mhatre's direct common stock holdings total 5,014 shares. The RSUs and options vest on May 14, 2027, or the date of the next annual shareholder meeting, with the options exercisable at $103.38 per share until May 14, 2036.
Repligen (RGEN) director Margaret Pax receives new RSU and stock option awards
Repligen Corp director Margaret Pax was granted 995 restricted stock units and options for 2,239 shares of common stock. Both awards vest on the earlier of May 14, 2027, or the next annual shareholder meeting, with the stock options having an exercise price of $103.38 per share and expiring on May 14, 2036. Following these transactions, Ms. Pax directly holds 3,011 shares of common stock.
Repligen (RGEN) director receives 995 RSUs and 2,239 options in equity grant
Repligen Corporation director Carrie Eglinton Manner received an equity grant consisting of 995 restricted stock units (RSUs) and stock options for 2,239 shares with an exercise price of $103.38. These awards, which are compensation-related and not open-market trades, will vest in full on the earlier of May 14, 2027, or the date of the company's next annual shareholder meeting. Following these grants, Manner holds 5,461 common shares and 2,239 stock options.
Repligen (RGEN) director granted RSUs and options in Form 4 filing
Repligen Corporation director Martin D. Madaus was granted 995 restricted stock units (RSUs) and stock options for 2,239 shares, as reported in a recent Form 4 filing. These equity awards, which are not open-market trades, will vest on the earlier of May 14, 2027, or the next annual shareholder meeting. Following these grants, Madaus directly holds 6,581 common shares, with additional shares held indirectly through trusts.
Repligen (NASDAQ: RGEN) director granted RSUs and options in equity award
Repligen (NASDAQ: RGEN) director Glenn P. Muir received an equity award consisting of 995 restricted stock units (RSUs) and stock options for 2,239 shares. The RSUs and options vest on the earlier of May 14, 2027, one year from the grant date, or the next annual shareholder meeting, with the options having an exercise price of $103.38 per share and expiring on May 14, 2036. Following these transactions, Muir directly holds 40,051 shares of common stock and 2,239 stock options, with RSU settlement deferred until after his director service ends.
Repligen Corp stock (US7607591002): bioprocessing specialist back in focus after latest earnings
Repligen Corp, a bioprocessing technology specialist, is back in focus after reporting strong Q1 2026 financial results and an updated outlook. The company supplies essential technologies like filtration and chromatography solutions for manufacturing complex biologic medicines, including therapies for cell and gene applications. Its business model relies on recurring demand for single-use products and partnerships with major biopharmaceutical producers, offering investors indirect exposure to the growing biologics market.
Repligen Shareholders Approve Directors, Auditor and Pay Plan
Repligen Corporation shareholders have approved the election of nine directors, ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, and endorsed the compensation plan for named executive officers in a non-binding advisory vote. The company held its 2026 Annual Meeting of Stockholders on May 14, 2026, with a significant quorum. An analyst rating indicates a "Buy" for RGEN stock with a $160.00 price target, while TipRanks' AI Analyst, Spark, rates RGEN as "Neutral" due to a mix of improving fundamentals and high valuation.
Repligen Corp stock (US7607591002): RBC upgrade and Q1 2026 earnings put bioprocessing specialist back in focus
Repligen Corp has gained renewed attention after RBC Capital Markets reinstated coverage with an “Outperform” rating and the company reported better-than-expected Q1 2026 earnings. The stock has seen a significant decline since January 2026, dropping around 37%, prompting investor questions despite solid fundamentals. RBC's upgrade and Repligen's profitability amidst a softer demand environment highlight the company's resilience and long-term potential in the bioprocessing sector.
Repligen shareholders approve board nominees and executive pay at annual meeting
Repligen Corporation shareholders have approved all nine director nominees and the company's executive compensation at its 2026 Annual Meeting of Stockholders. They also ratified Ernst & Young LLP as their independent registered public accounting firm. This follows a strong Q1 2026 performance with higher-than-anticipated earnings and revenue, and an "outperform" rating from RBC Capital.
Why Repligen (RGEN) Stock Is Trading Up Today
Repligen (RGEN) shares rose 2.9% after RBC Capital resumed coverage with an "outperform" rating and a $160 price target, signaling a potential return to mid-teens organic sales growth. The positive outlook is driven by expectations of a strengthening bioprocess market and diversified growth drivers. Despite a recent drop due to accelerating wholesale inflation, the stock is up 1.9% from its previous close, trading significantly below its 52-week high.
Repligen Shareholders Approve Directors, Auditor and Pay Plan - TipRanks.com
Repligen shareholders convened their 2026 Annual Meeting on May 14, 2026, where they elected nine directors, ratified Ernst & Young LLP as the independent auditor, and approved executive compensation. The strong support for these proposals signals shareholder backing for Repligen’s leadership and governance. TipRanks’ AI Analyst, Spark, rates RGEN as Neutral due to improving fundamentals offset by expensive valuation and neutral technical momentum.
Repligen (NASDAQ: RGEN) holders back board, auditor and pay plan
Repligen Corporation shareholders approved the election of all nine director nominees, ratified Ernst & Young LLP as their independent registered public accounting firm for 2026, and gave non-binding advisory approval to the compensation of named executive officers at their 2026 Annual Meeting. A quorum was established with 54,022,359 out of 56,399,274 outstanding common shares represented. The voting results for each proposal showed significant support, affirming the board, auditor, and executive pay plan.
Repligen stock coverage resumed at RBC with outperform rating
RBC Capital has resumed coverage on Repligen Corp. (NASDAQ:RGEN) with an outperform rating and a price target of $160, signaling a significant upside from its current price. The firm anticipates a return to mid-teens organic sales growth driven by bioprocess market strengthening and diversified growth drivers, despite a recent 35% year-to-date decline in the stock. This optimistic outlook coincides with Repligen's strong Q1 2026 financial results, which exceeded analyst expectations for both EPS and revenue.
Repligen Corp stock (US7607591002): bioprocessing specialist after earnings and 52?week low
Repligen Corp shares recently hit a 52-week low despite exceeding quarterly earnings expectations. The company specializes in supplying bioprocessing technologies for biologic drug manufacturing, focusing on filtration, chromatography, and process analytics. While its high valuation reflects growth expectations, investors should monitor future earnings and customer investment plans given the stock's volatility and sensitivity to biotech spending.
Repligen Corporation - Common Stock (NQ: RGEN)
This article provides recent news headlines for Repligen Corporation (RGEN), including updates on its stock performance and analyst insights. Notable movements recorded on April 23, 2024, and October 31, 2023, highlight its status as a leading gainer. An article from September 15, 2022, also discusses why the medical products maker might be a potential buy due to strong sales and boosted guidance.
Repligen Corporation stock hits 52-week low at $109.44 By Investing.com
Repligen Corporation (RGEN) stock has fallen to a 52-week low of $109.44, experiencing a 14.19% decrease over the past year and a 31% year-to-date decline. This drop occurs despite the company reporting strong Q1 2026 financial results, exceeding analyst expectations for EPS and revenue. InvestingPro analysis suggests the stock might be undervalued, potentially indicating a buying opportunity.
Repligen Corporation stock hits 52-week low at $109.44 By Investing.com
Repligen Corporation (RGEN) stock has fallen to a 52-week low of $109.44, representing a 14.19% decrease over the past year and a 31% year-to-date decline. Despite recent market pressures, InvestingPro analysis suggests the stock may be undervalued. The company recently reported strong Q1 2026 financial results, surpassing analyst expectations with an EPS of $0.48 and revenue of $194 million.
Repligen Corporation stock hits 52-week low at $109.44
Repligen Corporation's stock has fallen to a 52-week low of $109.44, representing a 14.19% decrease over the past year and a 31% drop year-to-date, despite the company reporting better-than-expected Q1 2026 financial results with an EPS of $0.48 and revenue of $194 million. InvestingPro analysis suggests the stock might be undervalued, offering a potential buying opportunity for investors.
Repligen Drops 5.4% Amid Sector-Wide Selling
Repligen Corporation (RGEN) shares fell 5.4% to $107.41 on Wednesday due to a sector-wide selloff that also impacted other bioprocessing equipment suppliers. The decline, marked by a trading volume of 1.0M shares and a market capitalization reduction to $6.1B, appears to be driven by broader market sentiment or macro concerns rather than company-specific issues. The synchronized nature of the drops among peers suggests investors are reassessing positions across the sector.
How Repligen’s Higher Profit Guidance and Softer Sales Outlook Will Impact Repligen (RGEN) Investors
Repligen (RGEN) reported higher Q1 2026 revenue and net income, alongside boosting its full-year adjusted EPS guidance while slightly reducing its revenue outlook. This shift emphasizes margin expansion and cost discipline, partly due to the divestiture of a non-core business. Investors are now focused on the company's ability to execute on profitability amidst ongoing demand volatility from smaller biotech customers.
Barclays Maintains an “Overweight Rating” on Repligen Corporation (RGEN)
Barclays has maintained an "Overweight rating" on Repligen Corporation (RGEN) and increased its price target to $160 from $145. This comes after Repligen opened a new Training & Innovation Center in Breda, Netherlands, expanding its global presence and showcasing its bioprocessing technology portfolio. The company, a global life sciences firm focused on bioprocessing technologies, is considered one of the best biotech stocks to invest in according to billionaire Steve Cohen.
Repligen Q1 2026 slides: revenue jumps 15%, China sales double
Repligen (NASDAQ:RGEN) reported strong Q1 2026 results, with revenue increasing 15% to $194 million and adjusted EPS reaching $0.48, exceeding analyst expectations. The company saw significant growth in its Analytics and Chromatography segments, with China revenue nearly doubling. Repligen raised its full-year 2026 adjusted EPS guidance and adjusted operating margin guidance due to the strong performance and strategic divestitures.
Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh
This article focuses on the number of shareholders for Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt, identified by the ticker R2GE34 on the BMFBOVESPA exchange. It indicates that the market is currently closed with no trades. The provided content is largely navigational boilerplate from the TradingView platform rather than specific financial data or news about the company.
Repligen (RGEN) CPO has 334 RSU shares withheld to cover taxes
Repligen Corp's Chief Product Officer, Brian Robb, had 334 common shares withheld from the release of restricted stock units (RSUs) to cover tax obligations. The shares were valued at $126.43 each, totaling $42K, and this was not an open-market sale but a standard tax-withholding disposition. Following this transaction, Robb directly holds 7,985 Repligen common shares.
Repligen (RGEN) director adds 2,434 shares via option exercise
Repligen (RGEN) director Glenn P. Muir exercised stock options to acquire 2,434 shares of Common Stock at $38.76 per share on May 7, 2026. This transaction was an option exercise without any reported share sales. Following the exercise, Muir directly holds 39,056 shares of Repligen Common Stock.
Repligen forecasts $1.97-$2.05 EPS on $803M-$833M 2026 revenue, as it targets 1 point margin lift by end of 2027
Repligen has provided a financial outlook for 2026, projecting earnings per share between $1.97 and $2.05 on revenues ranging from $803 million to $833 million. The company also announced a strategic goal to increase its margin by one percentage point by the end of 2027, indicating a focus on profitability and operational efficiency.
Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
Repligen Corporation (NASDAQ: RGEN) announced its participation in the Bank of America Securities 2026 Global Healthcare Conference, with CFO Jason Garland scheduled to present on May 12th at 10:00 am PT. A live webcast and replay will be available on the company's Investor Relations website. Repligen is a global life sciences company focused on bioprocessing technologies for manufacturing biological drugs.
Repligen's Q1 earnings & revenues beat estimates, stock rises
The article states that Repligen's Q1 earnings and revenues surpassed analyst estimates, leading to an increase in the company's stock price. No further details are provided in the given content.
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
Repligen (RGEN) reported strong first-quarter 2026 results, with adjusted earnings per share of 48 cents and total revenues of $194.3 million, both surpassing Zacks Consensus Estimates. The company's stock rose over 6% following the better-than-expected performance, driven by significant growth in chromatography and process analytics franchises. Despite trimming its 2026 revenue guidance slightly, Repligen raised its EPS outlook due to anticipated margin expansion.
Repligen Corporation (NASDAQ:RGEN) Q1 2026 Earnings Call Transcript
Repligen Corporation reported strong Q1 2026 results, exceeding earnings expectations with $0.48 EPS against an anticipated $0.38. The company achieved 15% reported revenue growth (11% organic) and expanded adjusted operating margin by 160 basis points. Key strategic initiatives include the launch of a transformation office, the sale of its Polymem business, and a new OEM partnership in China, all aimed at driving growth and margin expansion.
How Q1 Revenue Acceleration Expectations Could Reshape Repligen’s (RGEN) Long-Term Risk‑Reward Narrative
Repligen Corporation is preparing to report its Q1 earnings, with analysts expecting a 13.3% year-on-year revenue growth, reinforcing confidence in the company's profitability. This report will be critical in shaping the long-term investment narrative for Repligen, especially following its return to profitability in 2025. Investors are closely watching Q1 results and updated commentary to assess the durability of its growth and whether the business has successfully turned a corner.
Repligen’s (NASDAQ:RGEN) Q1 CY2026 Sales Beat Estimates
Repligen (NASDAQ:RGEN) reported Q1 CY2026 results with sales of $194.3 million, beating analyst estimates by 1.3%, and adjusted EPS of $0.48, a 24.9% beat. While the company raised its full-year Adjusted EPS guidance, its revenue guidance for the full year came in slightly below analysts' estimates. Following the report, the stock traded up 3.1%.
Repligen (RGEN) Shares Skyrocket, What You Need To Know
Repligen (RGEN) shares surged 7.3% after the biopharma manufacturing company reported strong first-quarter 2026 financial results. The company's adjusted earnings per share of $0.48 significantly beat Wall Street estimates, and Repligen raised its full-year profit outlook, overshadowing a slightly lowered revenue forecast. This positive news follows a recent dip in share price due to an executive stock sale.
Repligen Jumps 6.6% Amid Sector-Wide Rally
Repligen Corporation (RGEN) surged 6.6% to $126.03 on Tuesday, mirroring a broader rally across the medical instruments and supplies sector. This sector-wide momentum saw peers like RVTY and BRKR also gain significantly, suggesting a coordinated institutional shift rather than company-specific news. The rally, accompanied by elevated trading volume, indicates renewed investor interest in biomanufacturing and life sciences markets.
Repligen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
Repligen Corporation announced its earnings results for the first quarter ended March 31, 2026. The company reported a revenue increase to USD 194.26 million from USD 169.17 million in the prior year. Net income also rose to USD 8.33 million, resulting in basic and diluted earnings per share from continuing operations of USD 0.15.
Earnings Flash (RGEN) Repligen Corporation Posts Q1 Adjusted EPS $0.48 per Share, Vs. FactSet Est of $0.38
Repligen Corporation (RGEN) announced its Q1 adjusted EPS of $0.48 per share, surpassing the FactSet estimate of $0.38 per share. This indicates a stronger financial performance than anticipated by analysts for the quarter.
Repligen (NASDAQ: RGEN) posts 15% Q1 revenue growth and lifts 2026 EPS view
Repligen Corporation reported a strong first quarter for 2026, with revenue increasing by 15% to $194.3 million and adjusted diluted EPS rising to $0.48. The company also announced the divestiture of its Polymem filtration business, launched a Transformation Office to focus on margin expansion, and entered a new OEM partnership in China. For the full year 2026, Repligen reaffirmed its organic revenue growth guidance of 9%-13% and increased its adjusted EPS outlook to $1.97-$2.05.
Earnings Flash (RGEN) Repligen Corporation Posts Q1 Adjusted EPS $0.48 per Share, vs. FactSet Est of $0.38
Repligen Corporation (RGEN) reported Q1 adjusted EPS of $0.48 per share, surpassing the FactSet estimate of $0.38 per share. The company also announced Q1 revenue of $194.3 million, exceeding the FactSet estimate of $192.1 million. This financial update highlights Repligen's stronger-than-expected performance for the first quarter ended March 31, 2026.
Repligen: Q1 Earnings Snapshot
Repligen Corp. reported strong first-quarter results, with a profit of $8.3 million and adjusted earnings of 48 cents per share, exceeding Wall Street estimates of 38 cents per share. The company's revenue of $194.3 million also surpassed Street forecasts. Repligen anticipates full-year earnings between $1.97 and $2.05 per share.
